Jimena Miguez
Overview
Explore the profile of Jimena Miguez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Silva B, Ysrraelit M, Zanga G, Segamarchi M, Cragnolini C, Galleguillos L, et al.
Mult Scler Relat Disord
. 2025 Jan;
94:106275.
PMID: 39847855
The use of additional cladribine tablets treatment courses is becoming an option in patients with multiple sclerosis (MS) showing disease activity after treatment initiation. Despite the availability over the past...
2.
Silva B, Heriz A, Ayerbe J, Lazaro L, Casas M, Lopez P, et al.
Neurol Sci
. 2024 Sep;
45(12):5841-5848.
PMID: 39259243
Introduction: Cladribine was approved for Multiple Sclerosis (MS) in our country in 2018. A previous study by our group showed that its use among high efficacy therapies options has been...
3.
Silva B, Casales F, Donoso C, Varela L, Heriz A, Gonzalez C, et al.
Mult Scler Relat Disord
. 2024 Aug;
90:105830.
PMID: 39216455
Introduction: the increase of older adults living with Multiple Sclerosis (MS) is associated with higher use of high efficacy therapies (HETs) in a clinical practice. The are no data regarding...
4.
Carnero Contentti E, Lopez P, Patrucco L, Cristiano E, Miguez J, Silva B, et al.
Mult Scler Relat Disord
. 2024 Jul;
89():105771.
PMID: 39033591
Background: Immunosuppressive therapies as azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX) are widely prescribed as first-line treatment to prevent relapses in NMOSD. However, the rate of response to these...
5.
Rojas J, Alonso R, Luetic G, Patrucco L, Casas M, Silva B, et al.
Clin Neuropharmacol
. 2024 Jul;
47(4):120-127.
PMID: 39008542
Objective: The aim was to evaluate patient profiles, effectiveness and safety of cladribine (CLAD) in patients with relapsing-remitting multiple sclerosis in Argentina. Methods: This was a substudy included in RelevarEM...
6.
Carnero Contentti E, Lopez P, Pettinicchi J, Miguez J, Patrucco L, Cristiano E, et al.
J Neurol Sci
. 2024 Jun;
462:123099.
PMID: 38897155
Methods: We conducted a retrospective study involving NMOSD patients from the Argentinean MS and NMOSD registry (RelevarEM, NCT03375177). Treatment response at 6 months was categorized as "good" if the EDSS...
7.
Piedrabuena M, Correale J, Fiol M, Marrodan M, Rojas J, Alonso M, et al.
J Neurol Sci
. 2024 May;
461:123052.
PMID: 38797140
Background: Knowledge of the safety and efficacy of disease-modifying therapies (DMTs) in older patients with Multiple Sclerosis (pwMS) is limited due to their exclusion from clinical trials. Our purpose is...
8.
Carnero Contentti E, Lopez P, Pettinicchi J, Criniti J, Pappolla A, Miguez J, et al.
Mult Scler J Exp Transl Clin
. 2023 Oct;
9(4):20552173231205444.
PMID: 37854639
We aimed to evaluate mortality and causes of death among Argentinean neuromyelitis optica spectrum disorder (NMOSD) patients and identify predictors of death. Retrospective study included 158 NMOSD patients and 11...
9.
Alonso R, Casas M, Lazaro L, Fernandez Liguori N, Pita C, Cohen L, et al.
Mult Scler Relat Disord
. 2023 Aug;
79:104935.
PMID: 37634468
Background: Disease-modifying therapies (DMTs) in multiple sclerosis (MS) can be classified according to the efficacy in which they prevent inflammatory activity. To date, there are limited data regarding the use...
10.
Alonso R, Casas M, Lazaro L, Fernandez Liguori N, Pita C, Cohen L, et al.
Mult Scler J Exp Transl Clin
. 2023 Feb;
9(1):20552173231154712.
PMID: 36846108
Background: We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and...